title: Sensitization of pelvic afferent nerves in the in vitro rat urinary bladder-pelvic nerve preparation by purinergic agonists and cyclophosphamide pretreatment.
abstract: Effects of purinergic agonists (alpha,beta-meATP and ATP) and cyclophosphamide-induced cystitis on bladder afferent nerve (BAN) activity were studied in an in vitro bladder-pelvic nerve preparation. Distension of the bladder induced spontaneous bladder contractions that were accompanied by multiunit afferent firing. Intravesical administration of 40 and 130 microM alpha,beta-meATP increased afferent firing from 27 +/- 3 to 53 +/- 6 and 61 +/- 2 spikes/s, respectively, but did not change the maximum amplitude of spontaneous bladder contractions. Electrical stimulation on the surface of the bladder elicited action potentials (AP) in BAN. alpha,beta-meATP decreased the voltage threshold from 9.0 +/- 1.2 to 3.5 +/- 0.5 V (0.15-ms pulse duration) and increased the area of the APs (82% at 80-V stimulus intensity). These effects were blocked by TNP-ATP (30 microM). ATP (2 mM) applied in the bath produced similar changes in BAN activity. These effects were blocked by bath application of PPADS (30 microM). Neither TNP-ATP nor PPADS affected BAN activity induced by distension of the bladder. Cystitis induced by pretreatment of the rats with cyclophosphamide (100 mg/kg ip) increased afferent firing in response to isotonic bladder distension (10-40 cmH(2)O), decreased the threshold, and increased the area of evoked APs. The increase in afferent firing at 10 cmH(2)O intravesical pressure was reduced 52% by PPADS. These results indicate that purinergic agonists acting on P2X receptors and cystitis induced by cyclophosphamide can increase excitability of the BANs.
authors.affiliation: Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA 15261, USA. yyu+@pitt.edu
authors.forename: Yongbei
authors.initials: Y
authors.lastname: Yu
authors.forename: William C
authors.initials: WC
authors.lastname: de Groat
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000779:Anesthetics, Local / Q000494:pharmacology; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology*; D003556:Cystitis / Q000139:chemically induced / Q000473:pathology; D004594:Electrophysiology; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D008465:Mechanoreceptors / Q000502:physiology; D009475:Neurons, Afferent / Q000502:physiology*; D010388:Pelvis / Q000294:innervation; D058913:Purinergic Agonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D001743:Urinary Bladder / Q000294:innervation* / Q000502:physiology
chemical_list: D000779:Anesthetics, Local; D018906:Antineoplastic Agents, Alkylating; D058913:Purinergic Agonists; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate; D003520:Cyclophosphamide; D008012:Lidocaine; C002630:alpha,beta-methyleneadenosine 5'-triphosphate